Related Experiment Videos
[Safety, reactogenicity and immunological activity of a group A meningococcal polysaccharide vaccine for children 1-4
Insights
The group A meningococcal polysaccharide vaccine is safe and effective in children aged 1-4 years. A 25-microgram dose demonstrated optimal immunogenicity and low reactogenicity for this age group.
Area of Science:
- Immunology
- Vaccinology
- Pediatric Infectious Diseases
Background:
- Group A meningococcal disease poses a significant threat to children.
- Development of effective vaccines is crucial for prevention.
- Assessing vaccine safety and immunogenicity in target populations is essential.
Purpose of the Study:
- To evaluate the safety, reactogenicity, and immunological potency of a group A meningococcal polysaccharide vaccine.
- To determine the optimal dosage for children aged 1-4 years.
Main Methods:
- A controlled trial involving children aged 1-4 years.
- Administration of two vaccine doses: 15 and 25 micrograms of meningococcal polysaccharide.
- Monitoring of systemic reactions (fever) and local reactions (skin hyperemia).
- Measurement of antibody production to group A meningococcal polysaccharide.
Main Results:
- Both 15 and 25 microgram doses were safe and well-tolerated.
- Mild systemic reactions (transient fever) and local reactions (skin hyperemia) were observed.
- Antibody production was confirmed for both doses.
- The 25 microgram dose showed a longer-lasting elevated antibody level.
Conclusions:
- The group A meningococcal polysaccharide vaccine is safe and immunogenic in children aged 1-4 years.
- The 25 microgram dose is recommended as the optimal dose due to its favorable balance of immunogenicity and low reactogenicity.
Abstract:
In the controlled trial carried out among children aged 1-4 years, the safety, reactogenicity and immunological potency of group A meningococcal polysaccharide vaccine produced at the Gabrichevskiĭ Research Institute of Epidemiology and Microbiology (Moscow) were studied. The vaccine under test was introduced in two doses containing 15 and 25 micrograms of meningococcal polysaccharide. Both doses were shown to be safe, faintly reactogenic and immunologically potent. Systemic reactions were manifested by a transient rise in temperature to subfebrile levels in 19% and to 37.8-38.2 degrees C in 4.7% of the vaccinees. The temperature dropped to the normal level by the end of the first day following vaccination. At the site of injection skin hyperemia up to 2-3 cm in diameter was registered in 74% and up to 5-6 cm in diameter, in 6% of the vaccinees. Hyperemia disappeared on day 2 after vaccination. The production of antibodies to group A meningococcal polysaccharide occurred in response to both doses under test, and the elevated antibody level (in comparison to the initial one) was retained perceptibly longer in response to a dose of 25 micrograms; this dose, considering its low reactogenicity, was chosen as the optimal dose for children of the above age group.